CLAIM CARD
Mechanistically, the rationale for ACE inhibitors influencing aging-related cardiometabolic pathways centers on modulation of the renin-angiotensin system, which can affect vascular health, insulin sensitivity, and adiposity. Preclinical data and theoretical frameworks suggest potential benefits on endothelial function and oxidative stress. However, the human evidence from this corpus does not provide clear support. The clinical RCT by Zhang 2025 supports efficacy for blood pressure control, a key cardiometabolic risk factor, but its design does not assess aging-specific endpoints. Observational studies like Azizzadeh 2026, which explicitly examine vascular aging, report null findings, suggesting that in real-world populations, the benefit of ACE inhibitors may not extend beyond hypertension management to modify core aging trajectories.
Evidence grade: exploratory
Contradiction status: none
Publication: 9ab2e887-2e5b-429a-8d89-fd6d7813a028
Provenance: Derivation Web chain
Citation Support
source_1Lin 2026source_2Din 2026source_3Spiegeleer 2025source_4Shen 2025source_5Bene 2025